Pacific Biosciences of California (NASDAQ:PACB) develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.
Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia. The company has established a network of distribution and service partners to support instrument installation, training and ongoing technical support in key markets around the world.
Over its history, Pacific Biosciences has focused on advancing long-read sequencing capabilities, achieving milestones such as its initial public offering in 2010 and the launch of successive instrument generations to enhance throughput and data quality. Its technology has been applied to studies ranging from microbial genome sequencing to complex human genome analysis, reflecting its versatility in both basic and translational research.
Led by President and Chief Executive Officer Christian Henry, Pacific Biosciences continues to invest in research and development aimed at increasing the speed, accuracy and affordability of long-read sequencing. The company’s strategic initiatives include expanding its consumables business, enhancing software tools for data interpretation and forming collaborations to address emerging needs in genomics and precision medicine.
